Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection.
We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human immunodeficiency virus (HIV)-infected adults in Haiti. Compared with adults without HIV infection, vaccination in HIV-infected individuals resulted in lower vibriocidal responses against Vibrio cholerae O1, and there was a positive relationship between the CD4(+) T-cell count and vibriocidal responses following vaccination. Nevertheless, seroconversion occurred at a rate of 65% against the Ogawa serotype and 74% against the Inaba serotype in adults with HIV infection. These results suggest that the vaccine retains substantial immunogenicity in adults with HIV infection and may benefit this population by protecting against cholera.
Division of Global Health Equity, Brigham and Women's Hospital Department of Global Health and Social Medicine Partners in Health.
Louise C
LC
Ivers
Department of Medicine Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Richelle C
RC
Charles
Partners in Health.
Isabelle J
IJ
Hilaire
Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Leslie M
LM
Mayo-Smith
Division of Global Health Equity, Brigham and Women's Hospital Partners in Health.
Jessica E
JE
Teng
Partners in Health.
J Gregory
JG
Jerome
Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Jenna
J
Rychert
Department of Medicine Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Regina C
RC
LaRocque
Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Peng
P
Xu
Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Pavol
P
Kovácˇ
Department of Medicine Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Edward T
ET
Ryan
International Centre for Diarrhoeal Disease Research-Bangladesh, Dhaka.
Firdausi
F
Qadri
Partners in Health.
Charles P
CP
Almazor
Department of Global Health and Social Medicine Partners in Health.
Molly F
MF
Franke
Department of Medicine Department of Pediatrics, Harvard Medical School Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Jason B
JB
Harris
D000284:Administration, Oral; D000328:Adult; D001770:Blood Bactericidal Activity; D018791:CD4 Lymphocyte Count; D002771:Cholera / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D006205:Haiti; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D008297:Male; D050296:Microbial Viability; D008875:Middle Aged
D022121:Cholera Vaccines; D007070:Immunoglobulin A; C000588783:shanchol
Cholera vaccine; HIV; Shanchol (BivWC); immunogenicity